Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at email@example.com. Follow @suzannewriter on Twitter.
- Contact Suzanne
- Follow Suzanne on Google+
Articles by Suzanne Elvidge
The vaccine targets infections with Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B, and is given as four doses between 6 weeks and 18 months of age. Both of these infections can cause meningitis.
Vaccibody's lead therapeutic DNA vaccine, developed for the treatment of precancerous changes in the cervix caused by human papillomavirus (HPV) infection, is expected to move into the clinic in late 2013 once funding is in place, the company CEO Ole Henrik Brekke told FierceVaccines at BIO 2012.
There is no preventive vaccine or cure, but Genocea Biosciences has a prophylactic HSV-2 vaccine moving into a first in-human clinical trial in third quarter 2012, Chip Clark, president and CEO told FierceVaccines at BIO 2012. Seth Hetherington, CMO, was also at the meeting, presenting in the session "Therapeutic Vaccines Against Chronic Infectious Diseases: Vaccines versus Microbes Part 2."
Glenn Dranoff of the Cancer Vaccine Center at Dana-Farber Cancer Institute opened "Therapeutic Cancer Vaccines: Renewed Optimism for the Product Pipeline" at BIO 2012 with a positive note: "It's an exciting time for immunotherapy."
Grass pollen allergy vaccine not to be sneezed at
Biomay is developing a recombinant grass pollen allergy vaccine, known as BM32, that could cut symptoms after just three doses.
Radiotherapy is commonly used in the treatment of prostate cancer, and immunotherapy company Advaxis has seen some promising preclinical results when it combined its prostate cancer vaccine, ADXS-PSA (ADXS31-142), with a dose of radiation, in a study published in Cancer Immunology Immunotherapy.
The reovirus, a cold virus, has potential as a therapeutic cancer vaccine, as well as having anticancer activity in its own right.
The vaccine developer Genocea Biosciences has used its in-house proteomics screening technology, AnTigen Lead Acquisition System (ATLAS), to identify two potential candidates for C trachomatis vaccines.
New HPV vax could treat cancer rather than prevent it
A team of U.S. researchers has created a synthetic vaccine that was effective in treated animals with HPV-derived cancer, and could be a step towards a cancer treatment with fewer side effects, according to a paper published in Cancer Immunology, Immunotherapy.
CAD106, a vaccine co-developed by Novartis and Cytos that targets the amyloid β peptide, has shown early hints of immune responses in a clinical trial in people with Alzheimer's disease. This vaccine could have potential to slow the development of the disease.